MAIA Biotechnology Announces Efficacy Updates for THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
MAIA Biotechnology Amends Employment Agreements with Executive Officers
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
MAIA Biotech executives receive salary hikes and new terms
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Zomedica Pharmaceuticals (ZOM) Receives a Buy from Noble Financial
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Zomedica Pharmaceuticals (ZOM – Research Report) today and set a price target ...
SMA7h
How new SMA treatments are turning hope into reality
For columnist Alyssa Silva, advances in the development of SMA treatments have felt like glimmers of miracles.